1Lassen JF, Rasmussen K, Galloe A, et al. SORT-OUT Ⅲ : A Prospective Randomized Comparison of Zotarolimus-EIuting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease. TCT 2008.
2Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med, 2007,356:998-1008.
3Galloe A, Thuesen L, Kelhak H, et al. Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice. JAMA, 2008,299:409-416.
4Kandzafi DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol, 2006,19:405-413.
5Maeng M, Kaltoft A, Jensen LO, et al. Large-scale registry examining safety and effectiveness of Zotarolimus-Eluting and Siroli- mus-Eluting stents in patients with coronary artery disease. http://www, tctmd, corn/list, aspx? rid = 114, 2008-10-16/ 2009-02-15.
6Sousa JE. Updated Meta-analysis of Cypher clinical trials: early and late safety and efficacy, http.//www, tetmd, com/txlist, aspx? rid =594&trid =292, 2005-10-20/2009-02-15.
7Giulio Guagliumi. Optical coherence tomography for drug eluting stent safety (ODESSA). http ://www. tctmd, corn/list, aspx? rid = 1.14, 2008-10-14/2009-02-15.
